DSM-Firmenich stock: BEMT opens exclusive U.S. sunscreen window
Published on 11/11/2026 at 10:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSCommercial window for BEMT
- The FDA added bemotrizinol to the US sunscreen monograph in June 2026, the first new active filter since 1999.
- DSM-Firmenich supplies the ingredient under the Parsol Shield brand and holds 18 months of exclusive US marketing rights.
- Ultra Violette and Neutrogena launched early products, giving manufacturers a route into a newly opened US market.
DSM-Firmenich stock is linked to the US rollout of bemotrizinol, an ingredient that has become available in the first American sunscreens after a regulatory process spanning more than two decades. Latin Times reported that the US Food and Drug Administration added BEMT to the over-the-counter sunscreen monograph on June 9, 2026, with sales permitted from August 9.
The approval gives DSM-Firmenich a direct commercial position in a newly opened market. The company supplies the ingredient to sunscreen manufacturers under the Parsol Shield brand and holds 18 months of exclusive US marketing rights, according to the Latin Times report. The exclusivity period began with the first commercial launch.
Early launches test market demand
Ultra Violette launched its Unblock Screen SPF 50 at Sephora on August 31, followed by Neutrogena products listed online from September 17. The early products use BEMT in formulations aimed at broad-spectrum UVA and UVB protection. Wider availability depends on manufacturers completing formulation, labeling and listing requirements for over-the-counter products.
The commercial opportunity rests on BEMT's regulatory and formulation profile. The ingredient can be used at concentrations of up to 6 percent under the FDA framework and is described as photostable, broad-spectrum and free of the white cast associated with some mineral formulas. DSM-Firmenich submitted the data supporting the US clearance and has marketed the filter internationally for years.
Exclusive supply shapes the outlook
For investors, the exclusivity period provides a defined window in which DSM-Firmenich is the central supplier for US products using BEMT. The next indicators are the pace of brand launches, consumer adoption and the extent to which the ingredient contributes to the company's beauty-related sales. The opportunity does not remove execution risks, including the timing of customer rollouts and competition after exclusivity ends.
DSM-Firmenich stock traded at 105.15 euros on Lang & Schwarz at 10:10 CET on Wednesday, November 11, 2026.
DSM-Firmenich stock at a glance
- Company: DSM-Firmenich
- ISIN: CH1216478797
- Trading venue: Lang & Schwarz
- Price: 105.15 euros at 10:10 CET on November 11, 2026
European markets remain an important backdrop for investors, with the SMI among the regional reference indexes.
For more news and analyses on DSM-Firmenich stock, investors should watch the pace of US product launches and the development of demand for BEMT.
